Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34645812.
- Also identified by DOI 10.1038/s41467-021-26269-w and PMC identifier 8514514.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The acidic tumor microenvironment in melanoma drives immune evasion by up-regulating cyclic adenosine monophosphate (cAMP) in tumor-infiltrating monocytes. Here we show that the release of non-toxic concentrations of an adenylate cyclase (AC) inhibitor from poly(sarcosine)-block-poly(L-glutamic acid γ-benzyl ester) (polypept(o)id) copolymer micelles restores antitumor immunity. In combination with selective, non-therapeutic regulatory T cell depletion, AC inhibitor micelles achieve a complete remission of established B16-F10-OVA tumors. Single-cell sequencing of melanoma-infiltrating immune cells shows that AC inhibitor micelles reduce the number of anti-inflammatory myeloid cells and checkpoint receptor expression on T cells. AC inhibitor micelles thus represent an immunotherapeutic measure to counteract melanoma immune escape.
Medical subject headings
- Adenylyl Cyclase Inhibitors
- Adenylyl Cyclases
- Antineoplastic Agents
- Cyclic AMP
- Melanoma, Experimental
- Skin Neoplasms